PharmaWeek
Wed., July 2, 2008 |  PharmaWeek.com | Archives | Advertising | Your Account | CHI Conferences |  Subscribe |
Sales Contacts
For advertising information contact: 

Alan El Faye
VP, Advertising Sales - CA, Western US, Midwest, South Eastern US, Europe, Canada, Pacific Rim
213-300-3886 

Kay O. Christopher
Regional Sales Manager, Advertising Sales -New England, North Eastern US
860-693-2991

Tom Loughran
Regional Sales Manager, Advertising Sales -Midwest, South Eastern US, Europe
781-972-5482

Contact the Editor
PharmaWeek welcomes your feedback. Please contact Catherine Varmazis or Allison Proffitt for editorial inquiries. 

Link to Us! 
You are welcome to link to articles on our website. Contact Catherine Varmazis for details.

e-Prints & Reprints 
To post a full article from PharmaWeek or Bio-IT World on your website (not just a link), or for paper reprints, please contact:
Becky Mullaney
The YGS Group
717-399-1900 ext.110

Dear Colleague,
Welcome to this week's eNewsletter covering breaking R&D news and business insights, and featuring Genstruct CEO Keith Elliston on how his company's patience and persistence have paid off.
 

 
 
BREAKING R&D NEWS
 

Accidental Fungus Leads to Promising Cancer Drug
Reuters [June 29] A drug developed using nanotechnology and a fungus that contaminated a lab experiment may be broadly effective against a range of cancers, U.S. researchers reported on Sunday.  The drug, called lodamin, was improved in one of the last experiments overseen by Dr. Judah Folkman, a cancer researcher who died in January. Folkman pioneered the idea of angiogenesis therapy -- starving tumors by preventing them from growing blood supplies. More

Alzheimer's Drug Fails Clinical Trial
New York Times [July 1] A drug under development by Myriad Genetics to treat Alzheimer’s disease failed in a closely watched late-stage clinical trial, dealing another blow to efforts to combat the illness. More

Private Sector Called 'Crucial' to Medicine
San Diego Union-Tribune [June 24] Answering critics who accuse drug companies of reaping obscene financial reward for little that is innovative, a conservative think tank investigated how the companies turned publicly funded science into therapies for cancer, hypertension and arthritis.  A report released last week by the Manhattan Institute for Public Policy states that without drug company expertise, taxpayer-funded science would have languished. More

Introgen Stock Rises as Company Seeks FDA Approval of Cancer Drug
Austin Business Journal [June 30] Shares of Introgen Therapeutics Inc. rose more than 11 percent in early trading Monday on news that the company has applied with the U.S. Food and Drug Administration to market its newest cancer drug. More

 
 
BUSINESS INSIGHTS 
 

IBM CEO Survey Shows Hunger for Change in Life Sciences
Bio-IT World [June 25] There were five principal takeaways from IBM’s recent survey of life science CEOs. Chief among them was a hunger for change. Seventy-nine percent of the life science CEOs anticipated major change in the next few years. Talent concerns, regulatory issues, and market factors were the most commonly cited factors. More

ZymoGenetics Inks Deal to Borrow Up to $100M
Seattle Times [June 30] Healthcare investment fund Deerfield Management agreed to lend up to $100 million to ZymoGenetics in exchange for stock warrants and a potentially significant cut of Recothrom sales, the company said Monday. More

Analyst Says Bristol-Myers a Buyout Target
Forbes [June 27] A day after completing its acquisition of Kosan Biosciences for $190.0 million, or $5.50 per share, Bristol-Myers Squibb is hearing analysts speculate that its own acquisition isn't far off. More

Biotech Chief Quits AstraZeneca Arm
Financial Times [June 27] AstraZeneca was dealt a blow last week with the unexpected departure of the chief executive of the business it acquired last year to spearhead its diversification into biological medicines. More

California Bill Eases Life Science Taxes
San Jose Business Journal [June 27] The state Senate Revenue and Tax Committee unanimously approved a bill that will allow biotech companies to extend net operating loss carry forward across a longer period of time. More

 
 
LAST WEEK'S TOP STORY
 

U.S. Probe of Glaxo’s Paxil Widens
Wall Street Journal [June 20] A Justice Department investigation of GlaxoSmithKline PLC's handling of its blockbuster antidepressant drug Paxil, including its marketing and safety research, appears to be widening. More

For More Recent Articles >>

 

LIFE SCIENCE JOBS

Friedrich Miescher Institute for Biomedical Research - Part of the Novartis Research Foundation
Basel, Switzerland is looking for a Head of IT Systems & Infrastructure. You will manage a cutting-edge core server and network infrastructure, comprising Linux and Solaris, as well as a robust Windows and Macintosh environment. We look forward to receiving your application: human.resources@fmi.ch. click for more information

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics, 
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit:
 LSCDD

Lilly Singapore Center for Drug Discovery (LSCDD)- Senior Bioinformatics Scientist,
Contribute to the development of novel algorithms, data analysis methods and software tools for drug discovery as part of the Integrative Computational Sciences (ICS) department at LSCDD.  Work closely with informatics and software engineering peers at ICS, and collaborate with the Discovery IT organization in Europe and USA. The successful candidate will offer hands-on insight and expertise in tailored therapeutic informatics and statistical analyses at the post-genomic era. For additional information, or to apply visit:
 LSCDD   

Lilly Singapore Center for Drug Discovery (LSCDD) - Manager, Software Engineering (Integrative Computational Sciences)
Join the Integrative Computational Sciences (ICS) department at Lilly Singapore Centre for Drug Discovery (LSCDD),as Manager Software Engineering.  Lead the development of integrated applications to process and visualize data from cutting edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. Masters in Computer Science/Engineering or related discipline, 10+ years post graduation experience , 2 years management experience needed. For a complete job description and requirements or to apply visit: LSCDD 

Lilly Singapore Center for Drug Discovery(LSCDD) -Senior Software Engineer, 
Join a strong team of software engineers in our Integrative Computational Sciences (ICS) at LSCDD. Collaborate with, and help develop integrated applications to process and visualize data from cutting-edge technologies used by scientists at Lilly Research Labs (LRL) and the Drug Discovery Research (DDR) teams. The Software Engineering team provides computational tools and tailored software solutions that enable the global effort of Tailored Therapeutics; ‘The Right Drug, at The Right Dose for The Right Patient at The Right Time'. For additional information, or to apply visit:
 LSCDD  

Memorial Sloan-Kettering Cancer Center - Linux Systems Administrator - MSKCC Bioinformatics Core in Manhattan seeks Linux Systems Administrator. Install, configure and update monitor and troubleshoot HPC cluster, email and web servers.  Master's degree and 5 years experience with HPC, network security, Postfix, Apache, Tomcat, Grid Engine. Solaris, Email bicjobs@cbio.mskcc.org or www.mskcc.org #015429. EOE/AA 

Unilever - Mathematical Modeller (Research Scientist)
This research is leading to the requirement for integration of both biological and chemical data that may not be amenable to analysis through traditionally used techniques. The ability to work in multidisciplinary teams alongside biologists, chemists and statisticians plus enthusiasm for learning new science is critical for the role.   For a complete job description and to apply, please visit: https://unilever.recruitmax.com/ 

More Life Science Jobs ~ Add a Job Listing

 

FEATURED EVENTS

Multiplexed Genomics Tools: Targeting the Missing Links
Between Health and Disease - September 21-23, 2008 • Providence, RI

Next-Generation Sequencing Data Analysis -September 22-23, 2008 • Providence, RI

Barnett Educational Services, 2008 Schedule

To have your event featured here, contact Lynn Cloonan for more information.

 Email to a Friend 

FEATURE

Genstruct: Patience, Persistence, and Payoff
By John Russell

Finding the right business model for systems biology technology providers has been challenging — that’s hardly a new theme in biotech. Most systems biology pioneers were founded as platform providers but soon encountered difficulties growing their sales sufficiently to increase valuations. Genstruct, a pioneer in using computational approaches to infer mechanistic hypotheses from large experimental data sets, is no exception. Read More.

EXCLUSIVE WEBCAST

NEW! Life Science Webcasts from Bio-IT World and Cambridge Healthtech Media Group

Life Science Webcasts

Bio-IT World Expo
Video Highlights

Personalized Genetics: Advancements and Driving Change
Linda Avey, co-founder of 23andMe, delivers her keynote at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.
View the Webcast Now.

The Future of Personal Genomics
A distinguished panel of personal genomics experts discuss the future of personal genomics at the 2008 Bio-IT World Conference & Expo in Boston, April 30, 2008.  They include Dietrich Stephan (co-founder, Navigenics); George Church (Harvard Medical School);
Jeff Drazen (editor-in-chief, New England Journal Medicine); Fred Ledley (Bentley College); John Halamka (CIO, Harvard Medical School); and Linda Avey (23andMe). Bio-IT World Editor-in-Chief Kevin Davies moderates the discussion.
View the Webcast Now

Insight Pharma Reports

Systems Biology: A Disruptive Technology
This report focuses on current and future applications of Systems Biology in drug discovery and describes radically new concepts emerging from basic Systems Biology research. More Information

Custom Market Research Services
Our experienced research team will work with you to fully understand your needs in order to create and conduct a custom market research program that meets your objectives.
Learn More

Featured Content

Spain’s Emerging Biotech Revolution
The biotechnology sector is growing 10 percent faster in Spain than it is in the U.S. Driven by a culture, government and private sector that are open-minded and optimistic, Spain-based companies are emerging as leaders in this dynamic field. Discover how your business can capitalize on creative solutions from Spain-based enterprises. Download Now
 
 
  
  
  

Waters
Automate Method SOPs for Greater Efficiency and Fewer Errors with Waters® NuGenesis® Intelligent Procedure Manager
The Waters® NuGenesis® SDMS Intelligent Procedure Manager is a workflow software package designed to guide the laboratory analyst through a routine, comprehensive method standard operating procedure (SOP) and integrate results with a chromatography data system. The Intelligent Procedure Manager addresses the predominately manual activities required to perform an analytical method or test, reducing cycle times up to 50-75% as compared to a traditional paper trail with fewer opportunities for human error.  From late-stage development to final product quality control and lot release, Intelligent Procedure Manager can be applied to any lab environment where rigorous adherence to approved test methods and SOPs must be followed, including compliance requirements for cGMP operations.Download Now

This Bio•IT World Briefing On “Next-Generation Sequencing,”underwritten by GenomeQuest, Inc.,
presents a selection of feature stories, interviews,commentaries, conference reports, and editorials on the emergence, opportunities, and challenges posed by high-throughput sequencing. Covered in this collection: the launch of new platforms from Applied Biosystems and Helicos; new applications of nextgen sequencing; the rise of personal genomics; and informatics solutions to vexing problem of managing the vast volumes of next-gen data. Download now 

SGI's Meeting Today’s Computational Needs for Science
The quest to better understand disease mechanisms and find new treatments is driven by new laboratory technologies and ever-more sophisticated modeling and simulation efforts. As such, life sciences R&D investigations increasingly are relying on more powerful computing resources. The challenge is how to accommodate the broad mix of applications.
Addressing this issue, this paper produced by the Bio-IT World Custom Publishing Group discusses a new SGI Hybrid Computing Environment approach. It optimally uses shared memory systems, multi-processor clusters, and FPGAs to accelerate computational workflows. Download This Free Paper 

To have your white paper featured here, contact Lynn Cloonan for more information.


Cambridge
                                Healthtech InstitutePublished by Cambridge Healthtech Institute (CHI). Copyright © 2008, all rights reserved. No material may be reproduced electronically or in print without written permission from CHI, 250 First Ave., Needham, MA 02494-2814. For reprints and/or copyright permission, please contact The YGS Group, 1808 Colonial Village Lane, Lancaster, PA; 17601 717-399-1900 ext.110, or email: becky.mullaney@theYGSgroup.com